MUSA is the first clinically available surgical robot assistant for microsurgeons that is CE-certified (meaning it conforms with health, safety, and environmental protection standards of the European market).
To help speed its development, its Dutch creator Microsure has just overseen a €2.7m fundraise which will be used to step up MUSA’s clinical roll-out; following earliler delays caused by the pandemic.
The device has been developed by a team of engineers and surgeons and is compatible with current operating techniques, instruments and other operation room-equipment.
It scales down motion and filters out tremours to keep a steady hand at any time throughout every microsurgical procedure.
This can greatly improve clinical outcomes for various micro-surgical indications such as lymphatic-venous anastomosis, a procedure related to problems with the flow of lymph fluid in tissue. Other operations include repair of the distal nerve, which affects hand movement and sensation – plus vascularised tissue transplantation and several other complex microsurgical procedures.
The initial planned clinical roll-out of MUSA was seriously delayed due to the Covid-19 pandemic, giving the company the opportunity to also further develop a number of improvements to the current MUSA system, which will be available on the market in the course of 2022.
This funding round was led by Invest-NL, while the other 50 per cent of the funding came from the existing shareholders BOM Brabant Ventures and venture capital investor Innovation Industries, as well as from private investor Ten Cate Investeringsmaatschappij (TCIM).
In mid 2020, Microsure appointed Sjaak Deckers PhD as its new CEO, to lead the company into its next phase of market entry.
Deckers is an experienced medtech executive with broad product development experience, as CEO of two earlier MedTech startup companies, GTX Medical and Sapiens (Steering Brain Stimulation), and as venture partner at European Healthtech Builder NLC.
He also held senior management positions at Medtronic, Philips Healthcare and Philips Research, where his latest role was senior director business development (healthcare).
Responding to the funding boost, he said: “Despite the Covid-19 restrictions, our engineers have made tremendous improvements to the current MUSA system, and our clinical team gained further adoption experience of microsurgery in the Netherlands with the MUSA system.
“Microsure has attracted strong interest from multiple key sites, and users from across Europe to further advance its unique robot assisted microsurgical technology platform. This investment will help us expediting our further clinical validation and adoption across multiple sites. It will scale up our business presence, addressing the unique clinical needs for microsurgeons.”